T&P 新疆天阳律师事务所 德展健康 2025 年第二次临时股东会 新疆天阳律师事务所 关于德展大健康股份有限公司 2025 年第二次临时股东会 法律意见书 二○二五年九月 1 T&P 新疆天阳律师事务所 德展健康 2025 年第二次临时股东会 新疆天阳律师事务所 关于德展大健康股份有限公司 2025 年第二次临时股东会法律意见书 天阳证股字[2025]第 33 号 致：德展大健康股份有限公司 天阳证股字[2025]第 33 号 新疆天阳律师事务所 新疆天阳律师事务所（下称本所）接受德展大健康股份有限公司（下称 公司）的委托，委派本所常娜娜律师、尹杰律师出席公司 2025 年第二次临 时股东会，根据《中华人民共和国公司法》（下称《公司法》）、《中华人 民共和国证券法》（下称《证券法》）和《德展大健康股份有限公司章程》 （下称《公司章程》），按照律师行业公认的业务标准、道德规范和勤勉尽 责精神，对有关的文件和事实进行核查与验证，并出具法律意见。 本所律师已经对公司提供的与本次股东会有关的文件材料进行了核查验 证。在进行核查验证过程中，公司已向本所保证，其已提供了本所律师认为 的为出具本法律意见书所必需的材料，所 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-068 德展大健康股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会没有出现议案被否决的情形； 2、本次股东会没有涉及变更以往股东会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议召开时间为 2025 年 9 月 12 日下午 14:30 时 网络投票时间为 2025 年 9 月 12 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 12 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为：2025 年 9 月 12 日 9:15－15:00 期间的任意时间。 2、会议召开地点：新疆维吾尔自治区乌鲁木齐市水磨沟区昆仑东街 789 号 金融大厦 15 层德展健康会议室。 3、会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 4、会议召集人：公司董事会 5、现场会议主持 ...

Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, with a total of 5,381 enterprises reported from January to July 2025, marking an increase of 465 enterprises compared to the same period last year, representing a year-on-year growth of 9.46% [1][1][1] - The report indicates that the number of industrial enterprises in Xinjiang accounts for 1.03% of the national total [1][1][1] - The data presented is sourced from the National Bureau of Statistics and organized by Zhiyan Consulting, a leading industry consulting firm in China [1][1][1] Group 2 - The article references various listed companies related to the industrial sector, including Guanghui Energy, New Natural Gas, and others, indicating potential investment opportunities [1][1][1] - Zhiyan Consulting has been engaged in industry research for over a decade, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1][1][1] - The report titled "2025-2031 China Industrial Cloud Industry Market Deep Assessment and Investment Opportunity Forecast" is mentioned, suggesting a focus on future market trends and investment potential [1][1][1]

Group 1 - The recombinant protein concept sector rose by 0.03%, ranking fifth among concept sectors, with 17 stocks increasing in value [1] - Leading stocks in the sector included Chengdu Xian Dao, Baipu Sais, and Rejing Bio, which saw increases of 13.74%, 12.10%, and 5.07% respectively [1] - Stocks with the largest declines included Saiseng Pharmaceutical, *ST Wanfang, and Huiyu Pharmaceutical, which fell by 5.45%, 4.89%, and 3.31% respectively [1] Group 2 - The main capital flow into the recombinant protein concept sector showed a net outflow of 86 million yuan, with 15 stocks experiencing net inflows [2] - The stock with the highest net inflow was Dezhan Health, which saw a net inflow of 124 million yuan, followed by Yipin Hong, Chengdu Xian Dao, and Haoyuan Pharmaceutical with net inflows of 96.47 million yuan, 79.22 million yuan, and 65.75 million yuan respectively [2][3] Group 3 - In terms of capital inflow ratios, Dezhan Health, Haoyuan Pharmaceutical, and Yipin Hong had the highest net inflow rates at 15.06%, 10.07%, and 9.66% respectively [3] - The top stocks in the recombinant protein concept based on capital flow included Dezhan Health, Yipin Hong, Chengdu Xian Dao, and Haoyuan Pharmaceutical, with respective daily price changes of 4.85%, 1.29%, 13.74%, and 4.14% [3]

Group 1 - The CRO concept index increased by 2.88%, ranking 8th among concept sectors, with 56 stocks rising, including Baohua Pharmaceutical, Dezhan Health, and ST Weiming hitting the daily limit [1][2] - Notable gainers in the CRO sector included Yiqiao Shenzhou, Puris, and Baicheng Pharmaceutical, which rose by 10.65%, 8.59%, and 8.46% respectively [1][2] - The sector saw a net inflow of 1.876 billion yuan, with 39 stocks receiving net inflows, and 7 stocks attracting over 50 million yuan [2][3] Group 2 - The leading stock in terms of net inflow was WuXi AppTec, with a net inflow of 1.04 billion yuan, followed by Fosun Pharma, Dezhan Health, and Chengdu Xian Dao with net inflows of 233 million yuan, 126 million yuan, and 93.8 million yuan respectively [2][3] - The highest net inflow ratios were observed in Dezhan Health, ST Weiming, and Baohua Pharmaceutical, with ratios of 26.23%, 17.45%, and 16.34% respectively [3][4] - The trading volume and turnover rates for key stocks in the CRO sector showed significant activity, with WuXi AppTec having a turnover rate of 4.09% and a price increase of 8.02% [3][4]

Group 1 - The CRO concept sector increased by 2.88%, ranking 8th among concept sectors, with 56 stocks rising, including Baohua Pharmaceutical, Dezhan Health, and ST Unimed hitting the daily limit [1] - Notable gainers in the CRO sector included Yiqiao Shenzhou, Puris, and Baicheng Pharmaceutical, which rose by 10.65%, 8.59%, and 8.46% respectively [1] - The sector saw a net inflow of 1.876 billion yuan, with 39 stocks receiving net inflows, and 7 stocks exceeding 50 million yuan in net inflow, led by WuXi AppTec with 1.04 billion yuan [2][3] Group 2 - The top stocks by net inflow ratio included Dezhan Health, ST Unimed, and Baohua Pharmaceutical, with net inflow ratios of 26.23%, 17.45%, and 16.34% respectively [3] - The top stocks in the CRO concept by net inflow included WuXi AppTec, Fosun Pharma, and Dezhan Health, with net inflows of 1.04 billion yuan, 233.4 million yuan, and 126.1 million yuan respectively [3][4] - Stocks with significant declines included Sichuan Shuangma, ST Biology, and Hitec Biotech, which fell by 3.73%, 3.03%, and 2.67% respectively [1][6]

Core Insights - The company, Dezhan Health, announced that by the first half of 2025, the main structural construction of certain buildings in the Hainan Dezhong International Medical and Health Complex project will be completed, with other structural constructions progressing steadily [2] Company Developments - As of August 29, 2023, Dezhan Health confirmed through an interactive platform that the construction of the Hainan Dezhong International Medical and Health Complex is on track, with significant milestones achieved in the project timeline [2]

Group 1 - The core viewpoint of the article is that Dezhang Health (000813) is making progress on its Hainan Decheng International Medical and Health Complex project, with some main structures already topped off and others advancing steadily towards completion [1] Group 2 - As of August 29, 2023, the company responded to investor inquiries regarding the status of the project [1] - The project is expected to reach significant construction milestones by the first half of 2025 [1]

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

Group 1 - The core point of the news is that Shanghai Yueye has successfully auctioned and transferred all shares of Dezhan Health, eliminating a long-standing potential selling pressure in the market [1] - The shareholding structure of Dezhan Health has become clearer, with the largest shareholder being Xinjiang Kaidi Investment Co., Ltd. holding 19.54% and the second largest being Merrill Holdings Group Ltd. holding 8.87% [1] - The actual controller of the company is the State-owned Assets Supervision and Administration Commission of the People's Government of Xinjiang Uygur Autonomous Region [1] Group 2 - Dezhan Health is a leading domestic company engaged in the research, production, and sales of cardiovascular drugs [2] - The company is focusing on deepening its technology innovation strategy and expanding its business layout towards "pharmaceuticals + medical + health" [2] - Dezhan Health has established a collaboration with the Chinese Academy of Engineering and is actively promoting various research projects with renowned institutions [2] Group 3 - The company has made progress in its product pipeline, with IND application for WYY injection for stroke indications expected to be submitted in the second half of the year [2] - The company plans to submit a registration application for CBD raw materials to the FDA in the second half of the year, with production expected to commence in the second half of 2025 [2] - The company is also involved in clinical trials for various cancer-related products, including VGX-3100 for cervical precancerous lesions and new drug exploration for COPD and pancreatic cancer [2]